NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness (EDS) and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder (ADHD). The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.
Industry:
Pharmaceuticals Major